Scalable and Interoperable framework for a clinically diverse and generalizable sepsis Biorepository using Electronic alerts for Recruitment driven by Artificial Intelligence (short title: SIBER-AI)

项目摘要 脓毒症是世界范围内的一项重大健康挑战，与重大死亡风险相关。的关键 改善脓毒症的结局是一旦确诊就进行早期治疗， 更糟糕的结果。脓毒症是一种异质性疾病，因此尽管数十年的研究集中在各种 尽管脓毒症的各个方面，但仍有许多关于导致脓毒症的潜在机制的知识有待了解。 结果的差异。生物储存库的利用使研究人员有机会研究不同的 疾病的机制;然而，我们必须在疾病早期收集生物标本， 不同的时间点，以了解疾病的轨迹。此外，内部也有机会 重症监护研究，以多样化的患者人群登记的研究，以调查差异， 发生于败血症。因此，需要制定最佳做法和标准作业程序 其可以作为用于建立可扩展和可推广的脓毒症生物储存库的模板。这项建议 旨在1）开发一个集成的多模式临床，生理，挥发物组学和多组学生物储存库 由半自主筛选算法驱动的谱以富集脓毒症表型; 2）设计和测试新的 在救护车和急诊护理中富集的脓毒症人群中收集生物标本的方法 医院环境;和3）开发新的方法，以生物储存同意，符合临床 在败血症的背景下，最大限度地提高患者的代表性，并增强患者之间的信任和参与 患者和代理决策者。

PROJECT SUMMARY Sepsis is a major health challenge worldwide that is associated with a significant risk of mortality. The key to improved outcomes in sepsis is earlier treatment once diagnosed, with delays in therapy being associated with worse outcomes. Sepsis is a heterogenous disease, and thus despite decades of research focused on various aspects of sepsis, there still remains much to be learned about the underlying mechanisms that result in differences in outcomes. The utilization of biorepositories gives investigators the opportunity to study different mechanisms of disease; however, it is imperative that we collect biospecimens early on in disease and at different time point in order to understand disease trajectory. Furthermore, there are opportunities within critical care research to diversify the patient population enrolled in studies in order to investigate disparities that occur in sepsis. Thus, the need to develop best practices and standard operation procedures are required that may serve as templates for establishing scalable and generalizable sepsis biorepositories. This proposal aims to 1) develop an integrated multi-modal clinical, physiologic, volatilomic, and multi-omic biorepository profile driven by a semi-autonomous screening algorithm to enrich sepsis phenotypes; 2)design and test novel methods of biospecimen collection among enriched sepsis populations in both ambulance and acute care hospital environments ; and 3)develop novel approaches to biorepository consent that match the clinical context of sepsis, maximize representativeness among patients, and enhance trust and engagement among patients and surrogate decision-makers.